RG
BMRN icon

Redmile Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Redmile Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100,000
Closed -$8.56M – 76
2019
Q2 		$8.56M Buy
+100,000
New +$8.55M 0.24% 60

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Redmile Group's BMRN Position: Q2 2026 in Review

Redmile Group increased its BioMarin Pharmaceuticals (BMRN) stake by 53% in Q2 2026, buying an estimated $5M and bringing the position to 265,169 shares worth $15.2M. The position accounts for 1.02% of the portfolio, ranked #22.

Redmile Group first reported a position in BMRN in Q2 2014 and has held it in 13 quarters since. The position peaked at $42.4M in Q2 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Redmile Group held 265,169 shares of BioMarin Pharmaceuticals worth $15.2M as of Q2 2026.
  • Redmile Group bought 91,310 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $5M.
  • BioMarin Pharmaceuticals made up 1.02% of Redmile Group's portfolio in Q2 2026, its #22 holding.
  • Redmile Group first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 13 quarters since.
  • Redmile Group's BioMarin Pharmaceuticals position peaked at $42.4M in Q2 2023.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.